{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Chemotherapy",
      "Erythropoietin",
      "Granulocyte colony-stimulating factor",
      "Infections",
      "Iron"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Infektionen bei neutropenischen Patienten nach Chemotherapie manifestieren sich meistens durch Fieber (febrile Neutropenie, FN). Zu den wichtigsten Determinanten des FN-Risikos geh\u00f6ren der Chemotherapietyp, die Dosisintensit\u00e4t und patientenspezifische Faktoren. Bei einem FN-Risiko von 20\u202f% oder h\u00f6her wird die Granulopoese nach der Therapie prophylaktisch mit G\u2011CSF (\u201egranulocyte colony-stimulating factor\u201c) stimuliert. Eine An\u00e4mie sollte immer abgekl\u00e4rt und falls erforderlich entsprechend ihrer Ursache bei An\u00e4miebeschwerden behandelt werden. Wenn ein absoluter oder funktioneller Eisenmangel vorliegt, dann ist meistens eine intraven\u00f6se (i.v.) Eisensubstitution erforderlich. Erythropoesestimulierende Substanzen k\u00f6nnen nach Chemotherapie bei H\u00e4moglobin(Hb)-Werten unter 10\u202fg/dl (6,2\u202fmmol/l) verwendet werden. Bei chronischer An\u00e4mie und Hb-Werten unter 8\u20137\u202fg/dl (<\u202f5,0\u20134,3\u202fmmol/l) sollte die Indikation f\u00fcr die Transfusion von Erythrozytenkonzentraten prim\u00e4r anhand der individuellen klinischen Symptomatik gestellt werden."
      ],
      "CopyrightInformation": "\u00a9 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature."
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35476110",
  "DateCompleted": {
    "Year": "2022",
    "Month": "05",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "01",
    "Day": "31"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "04",
        "Day": "27"
      }
    ],
    "Language": [
      "ger"
    ],
    "ELocationID": [
      "10.1007/s00120-022-01831-6"
    ],
    "Journal": {
      "ISSN": "1433-0563",
      "JournalIssue": {
        "Volume": "61",
        "Issue": "5",
        "PubDate": {
          "Year": "2022",
          "Month": "May"
        }
      },
      "Title": "Der Urologe. Ausg. A",
      "ISOAbbreviation": "Urologe A"
    },
    "ArticleTitle": "[G-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer : Guidelines on supportive treatment part\u00a01].",
    "Pagination": {
      "StartPage": "537",
      "EndPage": "551",
      "MedlinePgn": "537-551"
    },
    "Abstract": {
      "AbstractText": [
        "Infections in patients with neutropenia following chemotherapy are mostly manifested as fever (febrile neutropenia, FN). Some of the most important determinants of the risk of FN are the type of chemotherapy, the dose intensity and patient-specific factors. When the risk of FN is 20% or more granulopoiesis is prophylactically stimulated with granulocyte colony stimulating factor (G-CSF) after the treatment. Anemia should always be clarified and if necessary be treated according to the cause when symptomatic. If an absolute or functional iron deficiency is present, intravenous iron substitution is mostly necessary. Erythropoiesis-stimulating agents can be used after chemotherapy with hemoglobin (Hb) levels less than 10\u202fg/dl (6.2\u202fmmol/l). In cases of chronic anemia and Hb levels less than 7-8\u202fg/dl (<4.3-5.0\u202fmmol/l) the indications for transfusion of erythrocyte concentrates should be assessed primarily based on the individual clinical symptoms."
      ],
      "CopyrightInformation": "\u00a9 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": ", Finkenhain\u00a08, 67661, Kaiserslautern, Deutschland. hlink@kabelmail.de."
          }
        ],
        "LastName": "Link",
        "ForeName": "Hartmut",
        "Initials": "H"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ],
    "VernacularTitle": "G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, An\u00e4mie bei Krebserkrankung : Supportivtherapieleitlinien, Teil 1."
  },
  "MedlineJournalInfo": {
    "Country": "Germany",
    "MedlineTA": "Urologe A",
    "NlmUniqueID": "1304110",
    "ISSNLinking": "0340-2592"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "143011-72-7",
      "NameOfSubstance": "Granulocyte Colony-Stimulating Factor"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Urologie. 2023 Feb;62(2):186",
      "PMID": "36719436"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications",
        "prevention & control"
      ],
      "DescriptorName": "Anemia"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"
    },
    {
      "QualifierName": [
        "chemically induced",
        "prevention & control"
      ],
      "DescriptorName": "Febrile Neutropenia"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology",
        "prevention & control"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Granulocyte Colony-Stimulating Factor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Neoplasms"
    }
  ]
}